Company profile
Connect Biopharma Holdings Limited logo

Connect Biopharma Holdings Limited

Pipeline1 asset

  • RademikibartCBP-201 / IL-4Rα / human monoclonal antibody / Inflammatory diseases
    Acute exacerbations of COPDPhase 2ongoingGlobalAcute exacerbations of asthmaPhase 2ongoingGlobalChronic asthmaongoing studies by SimcereChina

Latest news11 items

All news

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway into 2H 2027 – SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma

Enrollment • Phase 2Topline data expected early September 2026 Tue, Sep 1, 2026

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis – – Expect to report topline data from both Phase 2 Seabreeze STAT studies mid-2026 – – $20.2 million private placement financing

Presentation / Abstract • Phase 3Presentation Tue, Mar 31, 2026

Connect Biopharma Announces $20.2 Million Private Placement Financing

Funding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a clinical-stage biopharmaceutical company focused

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near ‑ maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with safety comparable to placebo – – Data presented during late-breaking oral presentation at 2026

Trial Results • Phase 3

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that the results of a

Presentation / Abstract • Phase 3
Connect Biopharma Holdings Limited • Endpoint Arena